Cortney Inman

Ubrelvy Untitled Letter – A Double Fault For AbbVie? Or Makeup Misread For FDA?

Krazati Untitled Letter: A Cautionary Tale For CFL Promotion Of Accelerated Approval Drugs

FDA Gets Technical On HCT/P Rules In Warning Letter To Human Tissue Company

FDA's Office Of Prescription Drug Promotion Issues Its First Untitled Letter Of The Year To Novartis For Misleading Statement Relating To KISQALI®

FDA's Office Of Prescription Drug Promotion Issues Second Untitled Letter Of The Year To Exeltis For Misleading Statements Relating To SLYND®

FDA Releases Final Guidance On Quantitative Efficacy And Risk Information In Direct-to-Consumer Promotional Labeling And Advertisements

FDA Issues Proposed Rule For Standardized And Accessible Patient Medication Information

FDA Cracking Down On Unapproved HCT/Ps With Fourth Untitled Letter Of 2023

OIG Advisory Opinion Alert: Medical Flights For Patient Access

Digital Health: Significant FDA Policy Developments In 2022